Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O75106
UPID:
AOC2_HUMAN
Alternative names:
Amine oxidase [copper-containing]; Semicarbazide-sensitive amine oxidase
Alternative UPACC:
O75106; A5PKW2; O00120; O75105; Q4TTW5; Q9UNY0
Background:
Retina-specific copper amine oxidase, also known as Amine oxidase [copper-containing] and Semicarbazide-sensitive amine oxidase, exhibits monoamine oxidase activity, specifically targeting 2-phenylethylamine and tryptamine. This enzyme's role extends to adipogenesis and signal modulation in the retina, highlighting its importance in metabolic and visual processes.
Therapeutic significance:
Understanding the role of Retina-specific copper amine oxidase could open doors to potential therapeutic strategies, particularly in metabolic regulation and visual function enhancement.